Additionally, caspase‐4/5/11 activators like TAK‐242, a TLR4 inhibitor studied for sepsis, have shown effectiveness in reducing inflammatory responses and are being considered for repurposing in cancer therapy.206, 207. Here, TLR4 is linked to cancer.